GB2280370A - Pharmaceutical composition for the treatment of chronic skin ulcers - Google Patents

Pharmaceutical composition for the treatment of chronic skin ulcers Download PDF

Info

Publication number
GB2280370A
GB2280370A GB9413939A GB9413939A GB2280370A GB 2280370 A GB2280370 A GB 2280370A GB 9413939 A GB9413939 A GB 9413939A GB 9413939 A GB9413939 A GB 9413939A GB 2280370 A GB2280370 A GB 2280370A
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
boric acid
skin ulcers
chronic skin
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9413939A
Other versions
GB9413939D0 (en
Inventor
Pierre Rochon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB9413939D0 publication Critical patent/GB9413939D0/en
Publication of GB2280370A publication Critical patent/GB2280370A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/22Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Description

2280370 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CHRONIC SKIN
ULCERS The present invention relates to improvements in More particularly, the invention is directed to a pharmaceutical composition for topical use in the treatment of chronic skin ulcers.
Persons suffering from diabetes are prone to ulceration of their extremities such as hands and feet, due to the high sugar content of the blood which impairs blood circulation. Skin ulcers are characterized by a loss of epidermis and at least part of the dermis, which generally leads to chronic bacterial infections. These infections seldom respond to systemic antibiotics since the poor circulatory system of a diabetic prevents an adequate supply of blood to the extremities, and thus of the antibiotics. Topical antibiotics, on the other hand, are ineffective in most bacterial skin infections Pnd may cause allergic contact dermatitis. As a result, the infection cannot be controlled and in order to prevent it from spreading to adjacent parts of the body, the diabetic has no other alternative but to undergo amputation of the infected extremity.
It is therefore an object of the present invention to overcome the above drawbacks and to provide a pharmaceutical composition for the treatment of chronic skin ulcers.
In accordance with the present invention, there is thus provided a pharmaceutical composition for treating chronic skin ulcers and comprising, as active ingredient, a mixture of 4-chloro-3,5dimethylphenol and boric acid, together with a therefor.
the field of topical dermatologic therapy.
pharmaceutically acceptable carrier - 2 Applicant has found quite unexpectedly that 4chloro-3,5-dimethylphenol when used in admixture with boric acid is highly effective for treating chronic skin ulcers. The composition of the invention not only enables the infection to be cleared up, but also promotes skin granulation without the formation of scars.
In a preferred embodiment of the invention, the composition comprises about 1 wt.% of 4-chloro-3,5dimethylphenol and about 6 wt.% of boric acid, based on the total weight of the composition. Preferably, the pharmaceutically acceptable carrier is water.
4-Chloro-3,5-dimethylphenol is preferably used in the form of a solution which is sold under the trademark DETTOL and contains about 5 wt.% of 4chloro3,5-dimethylphenol, about 8 wt.% of pine oil and about 9 wt.% of isopropyl alcohol, the remainder being water. Approximately 40 parts by volume of such a solution are admixed with about 7 parts by volume of boric acid, and the resulting solution is diluted with approximately 123 parts by volume of water. A preferred composition according to the invention thus comprises about 1 wt.% of 4-chloro-3,5-dimethylphenol, about 6 wt.% of boric acid, about 2 wt.% of pine oil and about 2 wt.;- of isopropyl alcohol, the remainder being water.
The pharmaceutical composition of the invention is applied to the wound area of the skin and maintained in contact therewith for a period of approximately 20 minutes, for example, by immersing the infected extremity in a bath containing the treating solution in the case where the skin ulcer is located on one's hand or foot. After immersion, the wound area with the treating solution 3 thereon is covered with a gauze bandage. Such a treatment is repeated every 12 hours until complete healing of the wound is achieved.
It is believed that 4-chloro-3,5-dimethylphenol and boric acid coact synergistically to suppress bacterial activity and stimulate cell growth. The healing process proceeds without the formation of scars.
The following non-limiting example illustrates the invention.
EXAMPLE
A pharmaceutical composition for treating skin ulcers was prepared by mixing the following ingredients:
- DETTOL: 400 ml - Boric acid 70 ml - Water: 1230 ml The resulting solution was applied to a chronic skin ulcer on a diabetic's foot by immersing the foot in a bath containing the solution, for a period approximately 20 minutes. After immersion, the wound area 20 with the treating solution thereon was covered with a of gauze bandage. This treatment was repeated every 12 hours. Complete healing of the ulcer was observed after approximately six months of treatment.
4 -

Claims (12)

1. A pharmaceutical composition for thetreatment of chronic skin ulcers, comprising as active ingredient a mixture of 4-chloro-3,5-dimethylphenol and boric acid, together with a pharmaceutically acceptable carrier therefor.
2. A pharmaceutical composition according to claim 1, comprising about 1 wt.% of 4-chloro-3,5-dimethylphenol and about 6 wt.% of boric acid, based on the total weight of the composition.
3. A pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutically acceptable carrier is water.
4. A pharmaceutical composition according to claim 1 or 2, further comprising about 8 wt.% of pine oil and about 9 wt.% of isopropyl alcohol, based on the total weight of the composition.
5. A pharmaceutical composition according to claim 1, comprising about 40 parts by volume of DETTOL (trademark), about 7 parts by volume of boric acid and about 123 parts by volume of water.
6. Use of 4-chlorc-3,5-dimethylphenol in admixture with boric acid for treating chronic skin ulcers.
7. Use of DETTOL (trademark) in admixture with boric acid for treating chronic skin ulcers.
8. A pharmaceutical composition according to claim 1, substantially as described herein.
9. 4-Chloro-3,5-dirnethylphenol together with boric acid for use as a pharmaceutical composition for topical administration.
10. 4-Chloro-3,5-dimethylphenol together with boric acid for the treatment of chronic skin ulcers.
11. Use of 4-chloro-3,5-dimethylphenol together with boric acid for the manufacture of a pharmaceutical composition for the treatment of chronic skin ulcers.
12. A combined preparation or pack for the treatment of chronic skin ulcers, which comprises (a) 4-chloro-3,5-dimethylphenol, and (b) boric acid, the components being present together in the same formulation or in separate formulations for simultaneous or sequential administration, and, where appropriate or desired, instructions for use of the components together or sequentially.
GB9413939A 1993-07-12 1994-07-11 Pharmaceutical composition for the treatment of chronic skin ulcers Withdrawn GB2280370A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2100314 CA2100314C (en) 1993-07-12 1993-07-12 Pharmaceutical composition for the treatment of chronic skin ulcers

Publications (2)

Publication Number Publication Date
GB9413939D0 GB9413939D0 (en) 1994-08-31
GB2280370A true GB2280370A (en) 1995-02-01

Family

ID=4151918

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9413939A Withdrawn GB2280370A (en) 1993-07-12 1994-07-11 Pharmaceutical composition for the treatment of chronic skin ulcers

Country Status (4)

Country Link
CA (1) CA2100314C (en)
DE (1) DE4424548A1 (en)
FR (1) FR2707497A1 (en)
GB (1) GB2280370A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100222301A1 (en) * 2010-02-06 2010-09-02 Javid Mihan Jafari Topical drug for treatment and/or prevention of diabetic neuropathy, microangiopathy and diabetic and non diabetic ulcers and wound infection

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100222301A1 (en) * 2010-02-06 2010-09-02 Javid Mihan Jafari Topical drug for treatment and/or prevention of diabetic neuropathy, microangiopathy and diabetic and non diabetic ulcers and wound infection
EP2353585A3 (en) * 2010-02-06 2012-02-22 Dr. Mihan Jafari Javid Topical drug for treatment and/or prevention of diabetic neuropathy, microangiopathy and diabetic and non diabetic ulcers and wound infection

Also Published As

Publication number Publication date
FR2707497A1 (en) 1995-01-20
CA2100314C (en) 1996-04-16
GB9413939D0 (en) 1994-08-31
CA2100314A1 (en) 1995-01-13
DE4424548A1 (en) 1995-01-19

Similar Documents

Publication Publication Date Title
EP0112852B1 (en) Pharmaceutical gel composition
US4725609A (en) Method of promoting healing
EP0789584B1 (en) Application of superoxide dismutase in liposomes
US4401651A (en) Wound-healing compositions containing povidone-iodine
CN105142728B (en) Compositions and methods for treating surface wounds
US4424232A (en) Treatment of herpes simplex
US20050181028A1 (en) Topical composition and method for treating occlusive wounds
JP2005505543A (en) Emu base preparation for wound treatment
US4735802A (en) Topical dermatological composition and method of treatment
Margraf et al. A trial of silver-zinc-allantoinate in the treatment of leg ulcers
US5116617A (en) Pharmaceutical composition for topical use in the treatment of the capillary fragility
US6465514B1 (en) Methods and compositions for the promotion of hair growth
RU2202362C2 (en) Composition for topical usage containing human epidermis factor growth
US6503946B1 (en) Preparation for warts
CA2100314C (en) Pharmaceutical composition for the treatment of chronic skin ulcers
KR960005144B1 (en) Topical composition for acceleration wound healing
EP0699443B1 (en) Elder-containing skin preparation
US5616619A (en) Topical composition for burn relief and method of use
RU2177314C2 (en) Composition eliciting antiseptic, reparative and analgetic properties
WO2005077402A1 (en) Honey based gel formulations
RU2781402C2 (en) Niosomal antimicrobial gel for treating diabetic ulcers, wounds, burns, including those infected with antibiotic-resistant microorganisms
US5576005A (en) Effectiveness of wart removal by compositions including propolis
AU687840B2 (en) Topical composition for burn relief and method of use
AU558482B2 (en) Pharmaceutical gel composition
US6395779B1 (en) Method of treatment using peroxidized lipids

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)